| Literature DB >> 30957624 |
Linn Arvidsson Strømnes1, Helene Ree1, Knut Gjesdal2,3, Inger Ariansen4.
Abstract
Background The goal of this literature review was to assess sex differences in the quality of life (QoL) in patients with atrial fibrillation ( AF ) and, if possible, to determine if these are due to AF . Methods and Results The electronic database PubMed was searched on January 23, 2018, using the search terms "QoL", gender differences, " AF " female, and gender to find potential articles that assessed sex differences in QoL in AF patients. In all, 851 articles were identified, from which 25 original studies were eligible for this systematic review. Female AF patients were found to have poorer QoL and more symptoms than male AF patients. They scored lower, predominantly on the physical component score of the Medical Outcomes Study Short-Form 36 Health Survey. Conclusions The available literature consistently describes poorer QoL in female AF patients but does not clearly address whether this is a reflection of sex differences seen in the general population or is related to AF per se. It is also questionable whether the relatively poorer QoL in women is large enough to be of clinical importance.Entities:
Keywords: atrial fibrillation; female; gender; quality of life
Mesh:
Year: 2019 PMID: 30957624 PMCID: PMC6507196 DOI: 10.1161/JAHA.118.010992
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Flow chart of reviewing process. AF indicates atrial fibrillation; EQ, EuroQoL; QoL, quality of life; SF, Short Form.
Self‐Reporting Questionnaires Measuring QoL Used in This Review Article
| Generic questionnaires on quality of life | |
| SF‐36: Medical Outcomes Study Short‐Form 36 Health Survey | SF‐36 is the most commonly used generic health survey. It measures physical and mental QoL by evaluating physical, social, and emotional functioning. It consists of 36 questions and standardized response choices, which are organized into 8 domains: physical functioning (PF), social functioning (SF), role limitation due to physical health problems (RP), role limitation due to emotional problems (RE), mental health (MH), vitality (VT), bodily pain (BP), and general health perceptions (GH). Items are combined to form the mental component summary (MCS) and the physical component summary (PCS). The MCS measures social functioning and role limitations due to vitality and emotional distress, whereas the PCS estimates physical health and role limitations due to physical difficulties and bodily pain. Scores range from 0 to 100, with higher scores indicating better functioning and higher QoL. |
| EQ‐5D Index and VAS: EuroQoL 5D | EQ‐5D is a generic questionnaire that consists of 2 parts; EQ‐5D Index and EQ‐5D Visual Analogue Scale (VAS). EQ‐5D Index assesses QoL in 5 dimensions (mobility, self‐care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of severity: no problems, some/moderate problems, or extreme problems. The EQ‐5D questionnaire gives 243 (35) possible health states. These states are converted into a single summary index by adding preference weights from population norms. The EQ‐5D Index ranges from 0 to 1, with a higher score indicating higher QoL, EQ VAS measures the individuals’ perceived health from 0 (worst imaginable health state) to 100 (best imaginable health state). |
| Questionnaires on mental health and fatigue | |
| HADS: The Hospital Anxiety and Depression Scale | HADS is a well‐established questionnaire developed to provide a reliable and valid rating scale for anxiety and depression in medical settings. Because it omits somatic symptoms of depression such as fatigue and appetite changes, it is widely used to detect false‐positive findings in medical patients. It is a 14‐item scale with scores ranging from 0 to 42, with higher scores indicating greater distress. |
| STAI: The State Trait Anxiety Inventory | STAI is a 40‐item questionnaire assessing both state anxiety (temporary feeling) and trait anxiety (general feeling). The purpose of the questionnaire is to measure the present level of anxiety and anxiety predisposition. The total score on both subscales ranges from 20 to 80, with higher scores indicating higher levels of anxiety. |
| MFI‐20: Multidimensional Fatigue Inventory‐20 | MFI‐20 is a 20‐item questionnaire assessing the severity of fatigue. It covers different aspects of fatigue: general, physical, mental fatigue, and reduced activity and motivation. Scores range from 4 to 20, with higher scores indicating more symptoms of fatigue. |
| BDI: Beck Depression Inventory | BDI is a 21‐item questionnaire measuring the severity of depression the past week. Scores range from 0 to 63, with higher scores indicating greater levels of depression. |
| AF disease‐specific questionnaires on symptoms and quality of life | |
| AF‐QoL: Atrial Fibrillation Quality of Life | AF‐QoL is a questionnaire that contains 18 items with 3 domains: psychological, physical, and sexual activity. Scores range from 0 to 100, with higher scores indicating better QoL. |
| AFEQT: Atrial Fibrillation Effect on Quality of Life | AFEQT is a 20‐item questionnaire assessing 4 domains in AF‐related QoL: daily activities, symptoms, treatment concerns, and treatment satisfaction. Scores range from 0 to 100, with higher scores indicating better QoL. |
| AF‐SCL: Symptom Checklist—Frequency and Severity Scale | AF‐SCL is a questionnaire that measures the patient's perception of arrhythmia‐related symptom frequency and severity over a 1‐week interval. Scores range from 0 to 64 on the frequency scale and 0 to 48 on the severity scale, with higher scores indicating greater symptom burden. |
| AFS/B: Atrial Fibrillation Symptom and Burden | AFS/B is a 2‐part questionnaire: atrial fibrillation symptom (AFS) and atrial fibrillation burden (AFB). AFS measures the effect of symptoms on daily life by a set of 8 questions classified into asymptomatic, mild, moderate, or severe. AFB measures disease and health‐care utilization by a set of 6 questions. Each question is classified into none, minimal, moderate, and severe burden. |
| AFSS: University of Toronto Atrial Fibrillation Severity Scale | AFSS is a 7‐item questionnaire that measures the patient's perception of AF disease burden including frequency, duration, and severity of episodes. Scores range from 0 to 35, with higher scores indicating greater AF symptoms severity. |
AF indicates atrial fibrillation; QoL, quality of life.
Summary of Studies Assessing Sex Differences in QoL in Patients With Unspecified AF: Paroxysmal, Persistent, and Permanent
| Author, Year of Publication | QoL Study Population, Form of AF | % Female | Design, Setting, and Objective | Assessment of QoL* | Results of QoL |
|---|---|---|---|---|---|
| Dagres et al (2007) | 5333 patients, all forms of AF | 42 |
Ambulant or hospitalized AF patients from 35 European countries. | EQ‐5D at baseline and at 1 year follow‐up. | Female patients had lower QoL both in EQ‐5D and EQ‐VAS ( |
| Roalfe et al (2012) | 1762 patients, all forms of AF | 47 |
Substudy of BAFTA, an RCT of warfarin vs aspirin for stroke prevention in AF patients in primary care. | SF‐12, EQ‐5D. | Female, but not male, AF patients had significantly lower EQ‐5D scores than a reference population (difference below MID), and lower MCS scores (above MID). Both female and male AF patients had (amazingly) higher PCS than a reference population (less than MID). No age‐adjusted comparison between sexes, but AF patients with mild disability (Rankin score <2) had higher scores (above MID) for PCS, MCS and ED‐5D Index. |
| Marvig et al (2015) | 1003 patients with AF (78%) or venous thromboembolism (VTE) (22%) |
38 AF |
EU‐PACT: European Pharmacogenetics of Anticoagulant Therapy study. | EQ‐5D assessed at baseline and at 3‐mo follow‐up. |
Results before intervention |
| Reynolds et al (2006) | 963 patients, new‐onset AF | 40 |
Multicenter registry of new‐onset AF or flutter, the FRACTAL cohort study. | SF‐12, AFSS, AF‐SCL at baseline and over 2.5 y. |
Female patients had 10% lower PCS, slightly lower MCS, and 40% higher symptom frequency and severity scores than male patients. |
| Hoegh et al (2016) |
873 patients with AF/flutter |
32 AF |
Danish Diet, Cancer and Health Study cohort: National Patient Registry data from AF patients and controls. | SF‐36. |
After adjustment for age and comorbidity, AF patients of both sexes had lower PCS and slightly lower MCS than non‐AF participants. |
| Hendriks et al (2014) | 534 patients with newly diagnosed AF | 41 |
Newly diagnosed AF patients compared with a national reference population. | SF‐36, HADS assessed baseline and at 2 y. |
Results before intervention |
| Groenveld et al (2011) | 437 permanent AF patients | 33 |
Rate Control Efficacy in Permanent Atrial Fibrillation II (RACE II); RCT of AF patients in hospitals randomized to lenient or strict heart rate control. | SF‐36, AFSS, MFI‐20 assessed at baseline, 1 year, and end of study. |
Results before intervention |
| Wynn et al (2014) | 362 patients with AF | 32 | AF patients referred to an electrophysiology clinic. Objective: Evalidate EHRA symptom classification in AF. | EQ‐5D, AFEQT. |
Sex did not have significant effect on any QoL measure. |
| Forleo et al (2007) | 170 patients with AF | 32 |
Highly symptomatic, drug‐refractory AF patients referred for radiofrequency catheter ablation. | SF‐36 at baseline and 6 mo after the procedure. |
Results before intervention |
| Kang (2009) | 129 patients with AF | 50 |
AF data analysis from outpatient clinics in United States and Korea. | SF‐36. | Americans: female patients had worse physical function but better mental health. In Koreans, female patients had (ns) both worse physical function and worse mental health than male patients. Age adjustment not specified. Americans and Koreans: Female AF patients had significantly lower PCS than male patients when controlling for ethnic group ( |
| Tsounis et al (2014) | 108 patients with AF | 36 |
AF patients in tertiary hospital. | SF‐36, EQ‐5D. | Female patients reported significantly lower scores in 5 of 8 SF‐36 scales (PF, RP, BP, SF and RE) and lower scores in EQ‐VAS and in the mobility dimension of EQ‐5D. Age adjustment not specified. |
| Jeong et al (2014) | 108 patients with AF | 26 |
Interview about QoL and type D personality. | SF‐12. | More female patients had PCS and MCS below 50 points, and independent predictors for this were female sex and type D personality. Age adjusted. |
| Sandhu et al (2017) | 100 patients with AF | 20 |
Prospective cohort study of AF patients referred for cardioversion. | SF‐36, AFEQT baseline and at 3‐mo follow‐up. |
Results before intervention |
Numbers followed by ± indicate mean±SD unless otherwise specified. SF‐36 summary scores are physical summary score (PCS) and mental component summary score (MCS). SF‐36 subscales referred to include physical functioning (PF), physical role (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), emotional role (RE), and mental health (MH). AF indicates atrial fibrillation; AFS/B, Trial Fibrillation Symptom and Burden; AFSS, University of Toronto Atrial Fibrillation Severity Scale; EHRA, European Heart Rhythm Association; EQ‐5D, generic questionnaire that consists of 2 parts; EQ‐5D Index and EQ‐5D Visual Analogue Scale (VAS); MID, minimal important difference; ns, nonsignificantly; QoL, quality of life; RCT, randomized controlled trial. SF‐36, Medical Outcomes Study Short‐Form 36 Health Survey.
Articles also included in Table 4.
Summary of Studies Assessing Sex Differences in QoL in Patients With Paroxysmal and/or Persistent AF
| Authors, Year of Publication | QoL Study Population, Form of AF | % Female | Methods | Assessment of QoL* | Results of QoL |
|---|---|---|---|---|---|
| Goette et al (2015) | 542 patients with AF | 43 | IMPULS: a prospective multicenter study on consecutive outpatients treated with dronedarone over 1 y. Objective: Investigate drug tolerability and efficacy. | EQ‐5D, AF‐QoL at baseline, 6 and 12 mo |
Results at baseline |
| Henry et al (2013) | 540 patients with AF | 34 |
Data collected from a hospital‐based surgical AF ablation registry (Cox Maze III/IV procedure). | SF‐12, AF‐SCL assessed at baseline and up to 24 mo |
Results before intervention |
| Rienstra et al (2005) | 458 patients with AF | 28 |
Post‐hoc QoL analysis of patients randomized to rate or rhythm control. | SF‐36 at baseline, 12 mo and end of study. |
Results before intervention |
| Paquette et al (2000) | 294 patients with symptomatic AF | 41 | Substudy of the Canadian Trial of Atrial Fibrillation where consecutive AF outpatients were randomized to amiodarone, sotalol, or propafenone treatment. Objectives: Elucidate sex differences in QoL and examine if personality characteristics could explain QoL impairment and QoL differences between sexes. | SF‐36, AFSS, AF‐SCL at baseline, 3 and 12 mo. |
Results before intervention |
| Pavelková and Bulava (2014) | 264 patients with AF | 40 |
Patients referred for catheter ablation at a tertiary clinic. | SF‐36 at baseline and within 12 mo |
Results before intervention |
| Koci et al (2014) | 224 patients with AF | 26 |
Consecutive patients from an electrophysiology center. | SF‐12, AFS/B. |
Female patients experienced more severe AF‐related symptoms, despite no sex difference in frequency and duration of AF episodes. They also reported significantly lower PCS and nonsignificantly lower MCS scores than male patients. |
| Wagner et al (2017) | 210 patients with AF | 28 |
RCT on catheter ablated AF patients: comprehensive rehabilitation or usual care (CopenHeartRFA trial). | SF‐36, HADS, AFEQT. |
Results after ablation, but before rehabilitation |
| Fiala et al (2017) | 202 patients with AF | 22 |
Single‐center prospective registry of long‐standing persistent AF patients who underwent catheter ablation. | EQ‐5D assessed at baseline and 12 mo |
Results before intervention |
| Berger et al (2016) | 99 patients with AF | 25 |
Patients completed SF‐36 at baseline and 1 y after catheter ablation. | SF‐36 assessed at baseline and 12 mo |
Results before intervention |
| Maryniak et al (2006) | 76 patients with AF | 29 |
AF patients referred for catheter ablation. | SF‐36 | No sex difference in any SF‐36 subscale. In female but not male patients, maximum ventricular rate during AF correlated negatively with the general physical feeling. Age adjustment not specified. |
Mean values followed by ± indicate mean±SD unless otherwise specified. SF‐36 summary scores are physical summary score (PCS) and mental component summary score (MCS). SF‐36 subscales referred to include physical functioning (PF), physical role (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), emotional role (RE), and mental health (MH). AF indicates atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality of Life; AF‐SCL, Symptom Checklist–Frequency and Severity Scale; AFS/B, Atrial Fibrillation Symptom and Burden; AFSS, University of Toronto Atrial Fibrillation Severity Scale; EQ‐5D, generic questionnaire that consists of 2 parts; EQ‐5D Index and EQ‐5D Visual Analogue Scale (VAS); HADS, The Hospital Anxiety and Depression Scale; QoL, quality of life; RCT, randomized controlled trial; SF‐36, Medical Outcomes Study Short‐Form 36 Health Survey.
Articles also included in Table 4.
Summary of Studies Assessing QoL in AF Patients After Intervention
| Authors, Year of Publication | QoL Study Population, Form of AF | % Female | Methods | Assessment of QoL* | Results of QoL |
|---|---|---|---|---|---|
| Rate vs rhythm control | |||||
| Groenveld et al (2011) | 437 patients with AF | 34 |
RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II); RCT of AF patients in hospitals randomized to lenient or strict heart rate control. | SF‐36, AFSS and MFI‐20 at baseline, 1 y and end of study. |
Female sex was associated with worsened SF‐36 MH scores (OR 2.3) and Mental Fatigue scores (OR 1.6 compared to male patients), from baseline to end of follow‐up study. |
| Rienstra, et al (2005) | 352 patients with AF | 36 |
Post‐hoc QoL analysis of patients randomized to rate or rhythm control. | SF‐36 at baseline, 12 mo and end of study. | QoL was unchanged in both sexes in both treatment arms. Baseline sex differences in QoL remained at the end of study, with female patients scoring lower on 7 of 8 SF‐36 scales. Age adjustment not explicitly specified. |
| Paquette et al (2000) | 264 symptomatic AF patients | 41 | Substudy of the Canadian Trial of Atrial Fibrillation in which consecutive AF outpatients were randomized to amiodarone, sotalol, or propafenone treatment. Objectives: Elucidate sex differences in QoL and examine if personality characteristics could explain QoL impairment and QoL differences between sexes. | SF‐36, AFSS, AF‐SCL at baseline and 3 and 12 mo. |
AF symptom frequency and severity at 12 mo had improved significantly for both sexes. PCS had improved significantly for female but not male patients, whereas MCS improved significantly for male but not female patients. |
| Sandhu et al (2017) | 100 patients with AF | 20 |
Prospective cohort study of AF patients referred for cardioversion. | SF‐36, AFEQT baseline and at 3‐mo follow‐up. |
Multivariable analysis showed that female sex, age, and sinus rhythm at 3 mo were associated with improved QoL after cardioversion. |
| AF patients undergoing ablation | |||||
| Henry et al (2013) | 148 patients with AF | 34 |
Data collected from a hospital‐based surgical AF ablation registry (Cox Maze III/IV procedure). | SF‐12, AF‐SCL assessed at baseline and up to 24 mo. | No sex difference in proportion that regained sinus rhythm. Female AF patients’ PCS and MCS scores were lower than those of male patients, and overall symptom frequency and severity scores were higher at all points of time. Both PCS and MCS improved in both sexes, surpassing age and sex group norms for PCS (female) and MCS (male). Overall AF symptom frequency and severity declined similarly in both sexes. PCS: Both male and female patients improved significantly between baseline and 6 mo. Female patients improved significantly from baseline to 12 mo and surpassed their age and sex group norms (by 3.6 points, |
| Forleo et al (2007) | 170 patients with AF | 32 |
Highly symptomatic, drug‐refractory AF patients referred for radiofrequency catheter ablation. | SF‐36 at baseline and 6 mo after the procedure. | At 6‐mo follow‐up, both sexes had improved SF‐36 scores. Women had numerically, but not statistically, better improvement than men. Age adjustment not specified. |
| Fiala et al (2017) | 202 male patients with AF mean age 57±9 y | 22 |
Single‐center prospective registry of long‐standing persistent AF patients who underwent catheter ablation. | EQ‐5D assessed at baseline and 12 mo. |
Female and male patients showed comparable improvement on EQ‐5D. |
| Berger et al (2016) |
99 patients with AF. | 25 |
Patients completed SF‐36 at baseline and 1 y after catheter ablation. | SF‐36 assessed at baseline and 12 mo. |
QoL improved significantly in all patients. No sex difference in any subscale of SF‐36 after ablation. |
| Other interventions | |||||
| Marvig et al (2015) | 1003 patients with AF (78%) or VTE (22%) |
38 AF |
EU‐PACT: European Pharmacogenetics of Anticoagulant Therapy study. | EQ‐5D assessed at baseline and at 3‐mo follow‐up. | Female AF patients had lower score than males on EQ‐5D, both at baseline and follow‐up. QoL improved after 3 mo on anticoagulant treatment, although less in AF than in VTE. EQ‐VAS improved in both sexes, but for EQ‐Index score, significantly only in men. No significant difference was seen between female and male patients in the VTE group. QoL data not age adjusted. |
| Wagner et al (2017) | 210 patients with AF | 28 |
RCT on catheter‐ablated AF patients: comprehensive rehabilitation or usual care (CopenHeartRFA trial). | SF‐36, HADS, AFEQT. | Comprehensive rehabilitation after ablation was better than usual care in women (AFEQT global and treatment concern scores), but in men only HADS‐anxiety was better. For SF‐36, no significant group difference was found from baseline to follow‐up, despite PCS and MCS improved numerically by >2 units for both intervention groups in both sexes. Data are age adjusted. |
Values followed by ± indicate mean±SD. SF‐36 summary scores are physical summary score (PCS) and mental component summary score (MCS). AF indicates atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality of Life; AF‐SCL, Symptom Checklist–Frequency and Severity Scale; AFSS, University of Toronto Atrial Fibrillation Severity Scale; DC, direct current; EQ‐5D, generic questionnaire that consists of 2 parts; EQ‐5D Index and EQ‐5D Visual Analogue Scale (VAS); HADS, The Hospital Anxiety and Depression Scale; OR, odds ratio; QoL, quality of life; RCT, randomized controlled trial; VTE, venous thromboembolism; SF‐36, Medical Outcomes Study Short‐Form 36 Health Survey.
Sex Difference in Mental Health in Patients With AF
| Authors, Year of Publication | QoL Study Population, Form of AF | % Female | Methods | Assessment of QoL* | Results of QoL |
|---|---|---|---|---|---|
| Akintade et al (2015) | 150 patients with AF (73%) and atrial flutter (27%) | 40 |
Cross‐sectional noninterventional study from teaching hospitals. | SF‐36, BDI‐II, STAI, AF‐SCL. | Female patients with AF/flutter reported poorer PCS and higher frequency and severity of AF‐related symptoms compared with male patients. Also, depressive symptoms were significant independent predictors of PCS. Symptoms of anxiety and depression were predictors of MCS. Age adjusted. |
| Ong et al (2006) | 93 patients with AF | 44 |
A cross‐sectional questionnaire study on AF patients from 2 tertiary‐care clinics. | SF‐36, HADS, AFSS. | Female patients had higher depression scores and used more antidepressants. Depression is associated with lower physical and mental QoL. Women scored almost 1 SD below the national norm for SF‐36 PCS, whereas men's scores were equal to norm data, as were MCS scores for both sexes. Female patients reported lengthier AF episodes, but episode frequency did not differ. Age adjustment not specified. |
Values followed by ± indicate mean value±SD. SF‐36 summary scores are physical summary score (PCS) and mental component summary score (MCS). AF indicates atrial fibrillation; AF‐SCL: Symptom Checklist‐Frequency and Severity Scale; AFSS: University of Toronto Atrial Fibrillation Severity Scale; BDI: Beck Depression Inventory; HADS: The Hospital Anxiety and Depression Scale; QoL, quality of life; SF‐36: Medical Outcomes Study Short‐Form 36 Health Survey; STAI: The State Trait Anxiety Inventory.
Risk of Bias in Assessing Differences in QoL in an AF Group Versus a Normal Population/Control Group, in Strata by Sex
| Studies | Selection Bias | Information Bias of Exposure and Confounders | Information Bias of Outcome | Bias Due to Confounding | Evaluation and Overall Risk of Bias |
|---|---|---|---|---|---|
| Studies comparing QoL in AF patients vs a normal population/control population in strata by sex | Systematic differences among groups regarding source population, recruitment strategy from source population, and participation rate. | Systematic differences among groups in how the exposure (AF status or control status) or confounders (age, comorbidity) were assessed. | Systematic differences among groups in how outcome (QoL) was measured (setting for filling out questionnaire) and questionnaire data were reported, handled and evaluated (complement rate for QoL questionnaires, method for missing responses, addressing of effect size for difference in QoL among groups). | Relevant confoundersidentified (age, comorbidity) and handled properly in analysis (such as adjusting or stratification). | Proper design to assess differences in QoL in an AF vs control population in strata by sex. Ability to consider bias and evaluation of bias. |
| Roalfe et al (2012) |
High Risk |
Low Risk |
Intermediate/high Risk |
Intermediate Risk |
Intermediate Risk |
| Marvig et al (2015) |
Low/intermediate Risk |
Intermediate Risk |
Low/intermediate Risk |
High Risk |
High Risk |
| Hoegh et al (2016) |
Low Risk |
Intermediate/Low Risk |
Low Risk |
Low Risk |
Low Risk |
| Hendriks et al (2014) |
High Risk |
Intermediate Risk |
Unknown |
High Risk |
High Risk |
| Henry et al (2013) |
High Risk |
Low Risk |
Unknown/Intermediate Risk |
Low/Intermediate Risk |
Intermediate/High Risk |
| Rienstra et al (2005) |
Unknown/High Risk |
High Risk |
Unknown/High Risk |
High Risk |
Intermediate/High Risk |
| Paquette et al (2000) |
High Risk |
High Risk |
Unknown/Intermediate |
Low/Intermediate |
Intermediate Risk |
| Berger et al (2016) |
High Risk |
Low Risk |
Unknown/Intermediate |
High Risk |
High Risk |
| Ong et al (2006) |
High Risk |
Intermediate Risk |
Low/Intermediate Risk |
Low/Intermediate Risk |
Intermediate/High Risk |
AF indicates atrial fibrillation; QoL, quality of life; MID, minimal important difference; RCT, randomized controlled trial.